1Cancer Statistics Center 2019 Estimates. American Cancer Society; 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Ovary.
2Lee P, Rosen DG, Zhu C, Silva EG, Liu J. (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecologic oncology. 3:671-677.
3Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, et.al. (1998) Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. Journal of experimental & clinical cancer research: CR. 2:231-237.
4Hatch KD, Beecham JB, Blessing JA, Creasman WT. (1991) Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 2:269-271.
5Markman M, Webster K, Zanotti K, Rohl J, Belinson J. (2004) Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecologic oncology. 2:390-393.
6Van Der Velden J, Gitsch G, Wain GV, Friedlander ML, Hacker NF. (1995) Tamoxifen in patients with advanced epithelial ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 4:301-305.
7Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2:112-117.
8Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH. (1993) An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Human pathology. 1:90-95.
9Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. (2010) Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. Journal of ovarian research. 3:14.
10Zhang ZJ, Li S. (2014) The prognostic value of metformin for
cancer patients with concurrent diabetes: a systematic review
and meta-analysis. Diabetes, obesity & metabolism. 8:707-710.
11Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen
Y, Chandarlapaty S, et al. (2011) Reciprocal feedback regulation
of PI3K and androgen receptor signaling in PTEN-deficient
prostate cancer. 5:575-586.
12Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto
KR. (2007) Cell- and gene-specific regulation of primary
target genes by the androgen receptor. Genes Dev. 16:2005-
2017.
13Pal SK, He M, Tong T, Wu H, Liu X, Lau C, et al. (2015)
RNA-seq reveals aurora kinase-driven mTOR pathway activation
in patients with sarcomatoid metastatic renal cell carcinoma.
Molecular cancer research: MCR. 1:130-137.
14Cancer Genome Atlas Research N. (2015) The Molecular
Taxonomy of Primary Prostate Cancer. Cell 4:1011-1025.
15Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina
A, et al. (2006) Gene expression signature-based chemical
genomic prediction identifies a novel class of HSP90 pathway
modulators. Cancer Cell 4:321-330.
16Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M,
White J, et al. (2002) The program of androgen-responsive
genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S
A. 18:11890-11895.
17Walters KA, Allan CM, Handelsman DJ (2008) Androgen
actions and the ovary. Biol Reprod.78:380-389.
18Hamilton TC, Young RC, McKoy WM, Grotzinger KR,
Green JA, Chu EW, et al. (1983) Characterization of a human
ovarian carcinoma cell line (NIH: OVCAR-3) with androgen
and estrogen receptors. Cancer Res. 11:5379-5389.
19Estep AL, Palmer C, McCormick F, Rauen KA. (2007) Mutation
analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer
cell lines: implications for therapy. PloS one. 12: e1279.
20Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR
pathway as a therapeutic target in endometrial cancer. Clinical
cancer research: an official journal of the American Association
for Cancer Research. 21:5856-5864.
21Aggarwal R, Zhang T, Small EJ, Armstrong AJ. (2014)
Neuroendocrine prostate cancer: subtypes, biology, and clinical
outcomes. Journal of the National Comprehensive Cancer
Network: JNCCN. 5:719-726.
22Tiffany Traine DYea.(2015) Results from a phase 2 study
of enzalutamide and AR inhibition in advanced AR positive
triple negative breast cancer. ASCO 2015.
23Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, et al. (2016) The
Correlation Between PARP1 and BRCA1 in AR Positive Triple-
negative Breast Cancer. International journal of biological
sciences. 12:1500-1510.
24Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee
A, Zhang Y, et al. (2015) Metformin inhibits ovarian cancer
growth and increases sensitivity to paclitaxel in mouse models.
American journal of obstetrics and gynecology. 4:479 e471-
479 e410.
25Romero IL, McCormick A, McEwen KA, Park S, Karrison
T, Yamada SD, et al. (2012) Relationship of type II diabetes and
metformin use to ovarian cancer progression, survival, and
chemosensitivity. Obstetrics and gynecology. 1:61-67.
26Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S,
Baladandayuthapani V, Kee BK, et al. (2012) Survival advantage
observed with the use of metformin in patients with type
II diabetes and colorectal cancer. British journal of cancer.
8:1374-1378.
27Lee S, Choi EJ, Jin C, Kim DH. (2005) Activation of PI3K/
Akt pathway by PTEN reduction and PIK3CA mRNA amplification
contributes to cisplatin resistance in an ovarian cancer
cell line. Gynecologic oncology. 1:26-34.